This is a dose-ranging study to evaluate the efficacy, safety and tolerability of a range of doses of a biphasic formulation of remogliflozin etabonate compared to placebo, administered over 12 weeks in subjects with type 2 diabetes mellitus.

Inclusion Criteria:

• Able to provide written informed consent
• Subject with clinical diagnosis of type 2 diabetes
• HbA1c 7.0 - 10.5% inclusive at Visit 1.

Exclusion Criteria:

• History of metabolic acidosis or ketoacidosis.
• Current active renal disease that is not related to hypertension or type 2 diabetes (e.g. non-diabetic glomerulonephritis, interstitial nephritis, symptomatic nephrolithiasis, etc.)
• Use of an investigational device or investigational drug within 30 days or 5 half-lives (whichever is longer) prior to Visit 1.